Pegfilgrastim: Current and future perspectives in the treatment of chemotherapy-induced neutropenia

Riccardo Ricotta, Giulio Cerea, Ilaria Schiavetto, Maria Rosaria Maugeri, Paolo Pedrazzoli, Salvatore Siena

Research output: Contribution to journalArticlepeer-review


Myeloid colony-stimulating factors (granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its potentially life-threatening complications. Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have demonstrated that a single, fixed, subcutaneous dose of pegfilgrastim is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells.

Original languageEnglish
Pages (from-to)667-676
Number of pages10
JournalFuture Oncology
Issue number6
Publication statusPublished - Dec 2006


  • Colony-stimulating factor
  • Granulocyte colony-stimulating factor
  • Hematopoietic growth factor
  • Neutropenia
  • Pegfilgrastim

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Pegfilgrastim: Current and future perspectives in the treatment of chemotherapy-induced neutropenia'. Together they form a unique fingerprint.

Cite this